Detalles de la búsqueda
1.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
2.
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Am J Hematol
; 97(12): 1607-1615, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36198076
3.
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients.
Int J Mol Sci
; 23(20)2022 Oct 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36293315
4.
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Hematol Oncol
; 39(1): 41-50, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33085797
5.
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Ann Hematol
; 96(12): 2071-2078, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29063955
6.
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Am J Hematol
; 90(7): 647-52, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25858483
7.
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Exp Cell Res
; 328(2): 444-55, 2014 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25257607
8.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood
; 120(1): 9-19, 2012 Jul 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22498745
9.
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Ann Hematol
; 93(1): 123-8, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23864035
10.
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Am J Hematol
; 89(12): 1085-91, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25159313
11.
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Expert Rev Anticancer Ther
; 24(6): 379-395, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38798125
12.
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features.
Nat Commun
; 15(1): 1551, 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38378709
13.
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients.
Cells
; 13(8)2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38667272
14.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Leukemia
; 38(3): 640-647, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38062124
15.
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.
Blood
; 118(23): 5989-95, 2011 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21900189
16.
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.
Haematologica
; 103(6): e277-e278, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29622654
17.
Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models.
Haematologica
; 103(12): e602-e606, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30026343
18.
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Clin Exp Med
; 23(8): 5227-5239, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37815734
19.
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.
Front Oncol
; 13: 1208741, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37305577
20.
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Haematologica
; 102(3): e104-e107, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27909220